Sign In
Last checked at 
2 Jan 2024 13:00
Syncona Limited
Total Voting Rights
2 January 2024
Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 December 2023 the total number of ordinary shares in issue stands at 671,806,666. The Company holds 8,091,779 ordinary shares in treasury which attract no voting rights.
Therefore, the total number of voting rights in the Company is 663,714,887. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries
Syncona Ltd
Annabel Clark
Tel: +44 (0) 7714 916615
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life. We do this by creating and building companies to deliver transformational treatments to patients in areas of high unmet need.
Our strategy is to create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses, across development stage and therapeutic areas, for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Follow the stocks
